PFIZER INC
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
PFE$29.23-0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
| Three Months Ended | ||
|---|---|---|
| (MILLIONS, EXCEPT PER SHARE DATA) | March 31,2024 | April 2,2023 |
| Revenues: | ||
| Product revenues(a) | $12,443 | $16,221 |
| Alliance revenues(a) | 2,172 | 2,060 |
| Royalty revenues(a) | 263 | 204 |
| Total revenues | 14,879 | 18,486 |
| Costs and expenses: | ||
| Cost of sales(b) | 3,379 | 4,886 |
| Selling, informational and administrative expenses(b) | 3,495 | 3,418 |
| Research and development expenses(b) | 2,493 | 2,505 |
| Acquired in-process research and development expenses | — | 21 |
| Amortization of intangible assets | 1,308 | 1,103 |
| Restructuring charges and certain acquisition-related costs | 102 | 9 |
| Other (income)/deductions––net | 680 | 275 |
| Income from continuing operations before provision/(benefit) for taxes on income | 3,421 | 6,270 |
| Provision/(benefit) for taxes on income | 293 | 715 |
| Income from continuing operations | 3,128 | 5,555 |
| Discontinued operations––net of tax | (5) | 1 |
| Net income before allocation to noncontrolling interests | 3,123 | 5,556 |
| Less: Net income attributable to noncontrolling interests | 8 | 13 |
| Net income attributable to Pfizer Inc. common shareholders | $3,115 | $5,543 |
| Earnings per common share––basic: | ||
| Income from continuing operations attributable to Pfizer Inc. common shareholders | $0.55 | $0.98 |
| Discontinued operations––net of tax | — | — |
| Net income attributable to Pfizer Inc. common shareholders | $0.55 | $0.98 |
| Earnings per common share––diluted: | ||
| Income from continuing operations attributable to Pfizer Inc. common shareholders | $0.55 | $0.97 |
| Discontinued operations––net of tax | — | — |
| Net income attributable to Pfizer Inc. common shareholders | $0.55 | $0.97 |
| Weighted-average shares––basic | 5,657 | 5,634 |
| Weighted-average shares––diluted | 5,697 | 5,727 |
(a)See Note 1A.
(b)Exclusive of amortization of intangible assets.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.